TimesSquare Capital Management’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-392,500
| Closed | -$67.5M | – | 232 |
|
|
2021
Q3 | $67.5M | Sell |
392,500
-122,495
| -24% | -$16M | 0.59% | 59 |
|
|
2021
Q2 | $64.6M | Sell |
514,995
-152,015
| -23% | -$19.2M | 0.53% | 74 |
|
|
2021
Q1 | $90.5M | Sell |
667,010
-120,945
| -15% | -$15.6M | 0.77% | 34 |
|
|
2020
Q4 | $101M | Sell |
787,955
-63,900
| -8% | -$7.49M | 0.82% | 26 |
|
|
2020
Q3 | $95.9M | Sell |
851,855
-124,565
| -13% | -$12.4M | 0.9% | 24 |
|
|
2020
Q2 | $93M | Sell |
976,420
-22,900
| -2% | -$2.21M | 0.89% | 19 |
|
|
2020
Q1 | $89.8M | Sell |
999,320
-126,255
| -11% | -$9.81M | 1.07% | 13 |
|
|
2019
Q4 | $59.7M | Buy |
1,125,575
+76,675
| +7% | +$3.5M | 0.53% | 80 |
|
|
2019
Q3 | $41.4M | Buy |
1,048,900
+131,930
| +14% | +$5.72M | 0.37% | 110 |
|
|
2019
Q2 | $37.7M | Sell |
916,970
-3,745
| -0.4% | -$155K | 0.29% | 136 |
|
|
2019
Q1 | $42.9M | Buy |
920,715
+209,900
| +30% | +$9.22M | 0.33% | 129 |
|
|
2018
Q4 | $31M | Sell |
710,815
-27,300
| -4% | -$1.36M | 0.27% | 143 |
|
|
2018
Q3 | $42.2M | Buy |
738,115
+361,460
| +96% | +$17.8M | 0.28% | 141 |
|
|
2018
Q2 | $18.3M | Buy |
376,655
+44,650
| +13% | +$1.63M | 0.12% | 207 |
|
|
2018
Q1 | $13M | Buy |
+332,005
| New | +$14.1M | 0.09% | 218 |
|
TimesSquare Capital Management's XLRN Position: Q4 2021 in Review
TimesSquare Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 392,500 shares — an estimated $67.5M sold.
TimesSquare Capital Management first reported a position in XLRN in Q1 2018 and held it in 15 quarters. The position peaked at $101M in Q4 2020. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- TimesSquare Capital Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- TimesSquare Capital Management sold 392,500 Acceleron Pharma shares in Q4 2021, an estimated $67.5M.
- TimesSquare Capital Management first reported a position in Acceleron Pharma in Q1 2018 and held it in 15 quarters.
- TimesSquare Capital Management's Acceleron Pharma position peaked at $101M in Q4 2020.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on TimesSquare Capital Management's 13F filing for Q4 2021, filed 4 Feb 2022.